Sucralfate acts locally in the gastrointestinal tract by forming an ulcer-adherent complex that protects the ulcer site from acid, pepsin, and bile salts.

Indicated for short-term treatment (up to 8 weeks) of active duodenal ulcer.

1 g (10 mL) four times daily on an empty stomach.

Most common: Constipation (2%)

Others (<0.5%): Diarrhea, dry mouth, gastric discomfort, nausea, rash, dizziness, headache

Sucralfate oral suspension is contraindicated for patients with known hypersensitivity reactions to the active substance or to any of the excipients.

Route Warning: Do not administer intravenously – associated with fatal embolic complications.

Use with Caution:

• Pregnant or pediatric patients

  • Patients with chronic renal failure due to aluminum accumulation risk

  • Diabetics – may cause episodes of hyperglycemia